Global New-Born Screening

New-Born Screening Comprehensive Study by Type (Tandem Mass Spectrometry, Pulse Oximetry Screening Technology, DNA-Based Assays, Hearing Screen Technology, Others), Application (Hospitals, Clinics, Nursing Homes, Others), Test (Dry blood spot tests, Hearing screening tests, CCHD screening tests), Technology (Immune assays & enzymatic assays, Tandem mass spectrometry, Molecular assays, Hearing screening technologies, Pulse oximetry, Other Technologies (Fluorescence, gel electrophoresis and etc.)), End User (Clinical Laboratories, Hospitals) Players and Region - Global Market Outlook to 2032

New-Born Screening Market by XX Submarkets | Forecast Years 2025-2032  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About New-Born Screening
Newborn screening is a public health initiative aimed at detecting certain severe genetic, metabolic, hormonal, and functional disorders in newborns that can be treated or controlled well if detected early. Newborn screening is usually done within the first 48 hours of birth and is a simple blood test where a small amount of blood is drawn from the heel of the baby and sent to a laboratory for testing. These screening tests diagnose a range of disorders, including phenylketonuria (PKU), cystic fibrosis, sickle cell disease, and congenital hypothyroidism, among others. Newborn screening for these conditions is important since many of these conditions, if left untreated, result in serious health issues, developmental delays, or even death. By detecting these conditions early, health care providers are able to initiate interventions, treatments, or therapies that can have a profound impact on the child's quality of life, development, and overall health outcomes. Newborn screening programs differ between countries and regions, with various lists of conditions being screened for depending on the local population's health needs and available resources. While newborn screening has become the norm in most areas of the world, ongoing discoveries in genetic analysis and medical research continue to push the boundaries for the conditions which can be screened, resulting in further advances in newborn care.

AttributesDetails
Study Period2020-2032
Base Year2024
UnitValue (USD Million)


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GE Healthcare (Chicago, United States), Trivitron Healthcare (Chennai, India), AB Sciex (Framingham, United States), PerkinElmer (Waltham, United States), Bio-Rad Laboratories (Hercules, United States), Agilent Technologies (Santa Clara, United States), Covidien (Mansfield, United States) (Note: Acquired by Medtronic), Masimo (Irvine, United States), Waters Corporation (Milford, United States) and Natus Medical (Pleasanton, United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global New-Born Screening market by Type (Tandem Mass Spectrometry, Pulse Oximetry Screening Technology, DNA-Based Assays, Hearing Screen Technology and Others), Application (Hospitals, Clinics, Nursing Homes and Others) and Region.



On the basis of geography, the market of New-Born Screening has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Test, the sub-segment i.e. Dry blood spot tests will boost the New-Born Screening market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Immune assays & enzymatic assays will boost the New-Born Screening market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Clinical Laboratories will boost the New-Born Screening market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.



About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Tandem Mass Spectrometry
  • Pulse Oximetry Screening Technology
  • DNA-Based Assays
  • Hearing Screen Technology
  • Others
By Application
  • Hospitals
  • Clinics
  • Nursing Homes
  • Others
By Test
  • Dry blood spot tests
  • Hearing screening tests
  • CCHD screening tests

By Technology
  • Immune assays & enzymatic assays
  • Tandem mass spectrometry
  • Molecular assays
  • Hearing screening technologies
  • Pulse oximetry
  • Other Technologies (Fluorescence, gel electrophoresis and etc.)

By End User
  • Clinical Laboratories
  • Hospitals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Factor Analysis
    • 3.1. Porters Five Forces
    • 3.2. Supply/Value Chain
    • 3.3. PESTEL analysis
    • 3.4. Market Entropy
    • 3.5. Patent/Trademark Analysis
  • 4. Global New-Born Screening, by Type, Application, Test, Technology, End User and Region (value) (2019-2024)
    • 4.1. Introduction
    • 4.2. Global New-Born Screening (Value)
      • 4.2.1. Global New-Born Screening by: Type (Value)
        • 4.2.1.1. Tandem Mass Spectrometry
        • 4.2.1.2. Pulse Oximetry Screening Technology
        • 4.2.1.3. DNA-Based Assays
        • 4.2.1.4. Hearing Screen Technology
        • 4.2.1.5. Others
      • 4.2.2. Global New-Born Screening by: Application (Value)
        • 4.2.2.1. Hospitals
        • 4.2.2.2. Clinics
        • 4.2.2.3. Nursing Homes
        • 4.2.2.4. Others
      • 4.2.3. Global New-Born Screening by: Test (Value)
        • 4.2.3.1. Dry blood spot tests
        • 4.2.3.2. Hearing screening tests
        • 4.2.3.3. CCHD screening tests
      • 4.2.4. Global New-Born Screening by: Technology (Value)
        • 4.2.4.1. Immune assays & enzymatic assays
        • 4.2.4.2. Tandem mass spectrometry
        • 4.2.4.3. Molecular assays
        • 4.2.4.4. Hearing screening technologies
        • 4.2.4.5. Pulse oximetry
        • 4.2.4.6. Other Technologies (Fluorescence, gel electrophoresis and etc.)
      • 4.2.5. Global New-Born Screening by: End User (Value)
        • 4.2.5.1. Clinical Laboratories
        • 4.2.5.2. Hospitals
      • 4.2.6. Global New-Born Screening Region
        • 4.2.6.1. South America
          • 4.2.6.1.1. Brazil
          • 4.2.6.1.2. Argentina
          • 4.2.6.1.3. Rest of South America
        • 4.2.6.2. Asia Pacific
          • 4.2.6.2.1. China
          • 4.2.6.2.2. Japan
          • 4.2.6.2.3. India
          • 4.2.6.2.4. South Korea
          • 4.2.6.2.5. Taiwan
          • 4.2.6.2.6. Australia
          • 4.2.6.2.7. Rest of Asia-Pacific
        • 4.2.6.3. Europe
          • 4.2.6.3.1. Germany
          • 4.2.6.3.2. France
          • 4.2.6.3.3. Italy
          • 4.2.6.3.4. United Kingdom
          • 4.2.6.3.5. Netherlands
          • 4.2.6.3.6. Rest of Europe
        • 4.2.6.4. MEA
          • 4.2.6.4.1. Middle East
          • 4.2.6.4.2. Africa
        • 4.2.6.5. North America
          • 4.2.6.5.1. United States
          • 4.2.6.5.2. Canada
          • 4.2.6.5.3. Mexico
  • 5. New-Born Screening: Manufacturers/Players Analysis
    • 5.1. Competitive Landscape
      • 5.1.1. Market Share Analysis
        • 5.1.1.1. Top 3
        • 5.1.1.2. Top 5
    • 5.2. Peer Group Analysis (2024)
    • 5.3. BCG Matrix
    • 5.4. Company Profile
      • 5.4.1. GE Healthcare (Chicago, United States)
        • 5.4.1.1. Business Overview
        • 5.4.1.2. Products/Services Offerings
        • 5.4.1.3. Financial Analysis
        • 5.4.1.4. SWOT Analysis
      • 5.4.2. Trivitron Healthcare (Chennai, India)
        • 5.4.2.1. Business Overview
        • 5.4.2.2. Products/Services Offerings
        • 5.4.2.3. Financial Analysis
        • 5.4.2.4. SWOT Analysis
      • 5.4.3. AB Sciex (Framingham, United States)
        • 5.4.3.1. Business Overview
        • 5.4.3.2. Products/Services Offerings
        • 5.4.3.3. Financial Analysis
        • 5.4.3.4. SWOT Analysis
      • 5.4.4. PerkinElmer (Waltham, United States)
        • 5.4.4.1. Business Overview
        • 5.4.4.2. Products/Services Offerings
        • 5.4.4.3. Financial Analysis
        • 5.4.4.4. SWOT Analysis
      • 5.4.5. Bio-Rad Laboratories (Hercules, United States)
        • 5.4.5.1. Business Overview
        • 5.4.5.2. Products/Services Offerings
        • 5.4.5.3. Financial Analysis
        • 5.4.5.4. SWOT Analysis
      • 5.4.6. Agilent Technologies (Santa Clara, United States)
        • 5.4.6.1. Business Overview
        • 5.4.6.2. Products/Services Offerings
        • 5.4.6.3. Financial Analysis
        • 5.4.6.4. SWOT Analysis
      • 5.4.7. Covidien (Mansfield, United States) (Note: Acquired by Medtronic)
        • 5.4.7.1. Business Overview
        • 5.4.7.2. Products/Services Offerings
        • 5.4.7.3. Financial Analysis
        • 5.4.7.4. SWOT Analysis
      • 5.4.8. Masimo (Irvine, United States)
        • 5.4.8.1. Business Overview
        • 5.4.8.2. Products/Services Offerings
        • 5.4.8.3. Financial Analysis
        • 5.4.8.4. SWOT Analysis
      • 5.4.9. Waters Corporation (Milford, United States)
        • 5.4.9.1. Business Overview
        • 5.4.9.2. Products/Services Offerings
        • 5.4.9.3. Financial Analysis
        • 5.4.9.4. SWOT Analysis
      • 5.4.10. Natus Medical (Pleasanton, United States)
        • 5.4.10.1. Business Overview
        • 5.4.10.2. Products/Services Offerings
        • 5.4.10.3. Financial Analysis
        • 5.4.10.4. SWOT Analysis
  • 6. Global New-Born Screening Sale, by Type, Application, Test, Technology, End User and Region (value) (2027-2032)
    • 6.1. Introduction
    • 6.2. Global New-Born Screening (Value)
      • 6.2.1. Global New-Born Screening by: Type (Value)
        • 6.2.1.1. Tandem Mass Spectrometry
        • 6.2.1.2. Pulse Oximetry Screening Technology
        • 6.2.1.3. DNA-Based Assays
        • 6.2.1.4. Hearing Screen Technology
        • 6.2.1.5. Others
      • 6.2.2. Global New-Born Screening by: Application (Value)
        • 6.2.2.1. Hospitals
        • 6.2.2.2. Clinics
        • 6.2.2.3. Nursing Homes
        • 6.2.2.4. Others
      • 6.2.3. Global New-Born Screening by: Test (Value)
        • 6.2.3.1. Dry blood spot tests
        • 6.2.3.2. Hearing screening tests
        • 6.2.3.3. CCHD screening tests
      • 6.2.4. Global New-Born Screening by: Technology (Value)
        • 6.2.4.1. Immune assays & enzymatic assays
        • 6.2.4.2. Tandem mass spectrometry
        • 6.2.4.3. Molecular assays
        • 6.2.4.4. Hearing screening technologies
        • 6.2.4.5. Pulse oximetry
        • 6.2.4.6. Other Technologies (Fluorescence, gel electrophoresis and etc.)
      • 6.2.5. Global New-Born Screening by: End User (Value)
        • 6.2.5.1. Clinical Laboratories
        • 6.2.5.2. Hospitals
      • 6.2.6. Global New-Born Screening Region
        • 6.2.6.1. South America
          • 6.2.6.1.1. Brazil
          • 6.2.6.1.2. Argentina
          • 6.2.6.1.3. Rest of South America
        • 6.2.6.2. Asia Pacific
          • 6.2.6.2.1. China
          • 6.2.6.2.2. Japan
          • 6.2.6.2.3. India
          • 6.2.6.2.4. South Korea
          • 6.2.6.2.5. Taiwan
          • 6.2.6.2.6. Australia
          • 6.2.6.2.7. Rest of Asia-Pacific
        • 6.2.6.3. Europe
          • 6.2.6.3.1. Germany
          • 6.2.6.3.2. France
          • 6.2.6.3.3. Italy
          • 6.2.6.3.4. United Kingdom
          • 6.2.6.3.5. Netherlands
          • 6.2.6.3.6. Rest of Europe
        • 6.2.6.4. MEA
          • 6.2.6.4.1. Middle East
          • 6.2.6.4.2. Africa
        • 6.2.6.5. North America
          • 6.2.6.5.1. United States
          • 6.2.6.5.2. Canada
          • 6.2.6.5.3. Mexico
  • 7. Appendix
    • 7.1. Acronyms
  • 8. Methodology and Data Source
    • 8.1. Methodology/Research Approach
      • 8.1.1. Research Programs/Design
      • 8.1.2. Market Size Estimation
      • 8.1.3. Market Breakdown and Data Triangulation
    • 8.2. Data Source
      • 8.2.1. Secondary Sources
      • 8.2.2. Primary Sources
    • 8.3. Disclaimer
List of Tables
  • Table 1. New-Born Screening: by Type(USD Million)
  • Table 2. New-Born Screening Tandem Mass Spectrometry , by Region USD Million (2019-2024)
  • Table 3. New-Born Screening Pulse Oximetry Screening Technology , by Region USD Million (2019-2024)
  • Table 4. New-Born Screening DNA-Based Assays , by Region USD Million (2019-2024)
  • Table 5. New-Born Screening Hearing Screen Technology , by Region USD Million (2019-2024)
  • Table 6. New-Born Screening Others , by Region USD Million (2019-2024)
  • Table 7. New-Born Screening: by Application(USD Million)
  • Table 8. New-Born Screening Hospitals , by Region USD Million (2019-2024)
  • Table 9. New-Born Screening Clinics , by Region USD Million (2019-2024)
  • Table 10. New-Born Screening Nursing Homes , by Region USD Million (2019-2024)
  • Table 11. New-Born Screening Others , by Region USD Million (2019-2024)
  • Table 12. New-Born Screening: by Test(USD Million)
  • Table 13. New-Born Screening Dry blood spot tests , by Region USD Million (2019-2024)
  • Table 14. New-Born Screening Hearing screening tests , by Region USD Million (2019-2024)
  • Table 15. New-Born Screening CCHD screening tests , by Region USD Million (2019-2024)
  • Table 16. New-Born Screening: by Technology(USD Million)
  • Table 17. New-Born Screening Immune assays & enzymatic assays , by Region USD Million (2019-2024)
  • Table 18. New-Born Screening Tandem mass spectrometry , by Region USD Million (2019-2024)
  • Table 19. New-Born Screening Molecular assays , by Region USD Million (2019-2024)
  • Table 20. New-Born Screening Hearing screening technologies , by Region USD Million (2019-2024)
  • Table 21. New-Born Screening Pulse oximetry , by Region USD Million (2019-2024)
  • Table 22. New-Born Screening Other Technologies (Fluorescence, gel electrophoresis and etc.) , by Region USD Million (2019-2024)
  • Table 23. New-Born Screening: by End User(USD Million)
  • Table 24. New-Born Screening Clinical Laboratories , by Region USD Million (2019-2024)
  • Table 25. New-Born Screening Hospitals , by Region USD Million (2019-2024)
  • Table 26. South America New-Born Screening, by Country USD Million (2019-2024)
  • Table 27. South America New-Born Screening, by Type USD Million (2019-2024)
  • Table 28. South America New-Born Screening, by Application USD Million (2019-2024)
  • Table 29. South America New-Born Screening, by Test USD Million (2019-2024)
  • Table 30. South America New-Born Screening, by Technology USD Million (2019-2024)
  • Table 31. South America New-Born Screening, by End User USD Million (2019-2024)
  • Table 32. Brazil New-Born Screening, by Type USD Million (2019-2024)
  • Table 33. Brazil New-Born Screening, by Application USD Million (2019-2024)
  • Table 34. Brazil New-Born Screening, by Test USD Million (2019-2024)
  • Table 35. Brazil New-Born Screening, by Technology USD Million (2019-2024)
  • Table 36. Brazil New-Born Screening, by End User USD Million (2019-2024)
  • Table 37. Argentina New-Born Screening, by Type USD Million (2019-2024)
  • Table 38. Argentina New-Born Screening, by Application USD Million (2019-2024)
  • Table 39. Argentina New-Born Screening, by Test USD Million (2019-2024)
  • Table 40. Argentina New-Born Screening, by Technology USD Million (2019-2024)
  • Table 41. Argentina New-Born Screening, by End User USD Million (2019-2024)
  • Table 42. Rest of South America New-Born Screening, by Type USD Million (2019-2024)
  • Table 43. Rest of South America New-Born Screening, by Application USD Million (2019-2024)
  • Table 44. Rest of South America New-Born Screening, by Test USD Million (2019-2024)
  • Table 45. Rest of South America New-Born Screening, by Technology USD Million (2019-2024)
  • Table 46. Rest of South America New-Born Screening, by End User USD Million (2019-2024)
  • Table 47. Asia Pacific New-Born Screening, by Country USD Million (2019-2024)
  • Table 48. Asia Pacific New-Born Screening, by Type USD Million (2019-2024)
  • Table 49. Asia Pacific New-Born Screening, by Application USD Million (2019-2024)
  • Table 50. Asia Pacific New-Born Screening, by Test USD Million (2019-2024)
  • Table 51. Asia Pacific New-Born Screening, by Technology USD Million (2019-2024)
  • Table 52. Asia Pacific New-Born Screening, by End User USD Million (2019-2024)
  • Table 53. China New-Born Screening, by Type USD Million (2019-2024)
  • Table 54. China New-Born Screening, by Application USD Million (2019-2024)
  • Table 55. China New-Born Screening, by Test USD Million (2019-2024)
  • Table 56. China New-Born Screening, by Technology USD Million (2019-2024)
  • Table 57. China New-Born Screening, by End User USD Million (2019-2024)
  • Table 58. Japan New-Born Screening, by Type USD Million (2019-2024)
  • Table 59. Japan New-Born Screening, by Application USD Million (2019-2024)
  • Table 60. Japan New-Born Screening, by Test USD Million (2019-2024)
  • Table 61. Japan New-Born Screening, by Technology USD Million (2019-2024)
  • Table 62. Japan New-Born Screening, by End User USD Million (2019-2024)
  • Table 63. India New-Born Screening, by Type USD Million (2019-2024)
  • Table 64. India New-Born Screening, by Application USD Million (2019-2024)
  • Table 65. India New-Born Screening, by Test USD Million (2019-2024)
  • Table 66. India New-Born Screening, by Technology USD Million (2019-2024)
  • Table 67. India New-Born Screening, by End User USD Million (2019-2024)
  • Table 68. South Korea New-Born Screening, by Type USD Million (2019-2024)
  • Table 69. South Korea New-Born Screening, by Application USD Million (2019-2024)
  • Table 70. South Korea New-Born Screening, by Test USD Million (2019-2024)
  • Table 71. South Korea New-Born Screening, by Technology USD Million (2019-2024)
  • Table 72. South Korea New-Born Screening, by End User USD Million (2019-2024)
  • Table 73. Taiwan New-Born Screening, by Type USD Million (2019-2024)
  • Table 74. Taiwan New-Born Screening, by Application USD Million (2019-2024)
  • Table 75. Taiwan New-Born Screening, by Test USD Million (2019-2024)
  • Table 76. Taiwan New-Born Screening, by Technology USD Million (2019-2024)
  • Table 77. Taiwan New-Born Screening, by End User USD Million (2019-2024)
  • Table 78. Australia New-Born Screening, by Type USD Million (2019-2024)
  • Table 79. Australia New-Born Screening, by Application USD Million (2019-2024)
  • Table 80. Australia New-Born Screening, by Test USD Million (2019-2024)
  • Table 81. Australia New-Born Screening, by Technology USD Million (2019-2024)
  • Table 82. Australia New-Born Screening, by End User USD Million (2019-2024)
  • Table 83. Rest of Asia-Pacific New-Born Screening, by Type USD Million (2019-2024)
  • Table 84. Rest of Asia-Pacific New-Born Screening, by Application USD Million (2019-2024)
  • Table 85. Rest of Asia-Pacific New-Born Screening, by Test USD Million (2019-2024)
  • Table 86. Rest of Asia-Pacific New-Born Screening, by Technology USD Million (2019-2024)
  • Table 87. Rest of Asia-Pacific New-Born Screening, by End User USD Million (2019-2024)
  • Table 88. Europe New-Born Screening, by Country USD Million (2019-2024)
  • Table 89. Europe New-Born Screening, by Type USD Million (2019-2024)
  • Table 90. Europe New-Born Screening, by Application USD Million (2019-2024)
  • Table 91. Europe New-Born Screening, by Test USD Million (2019-2024)
  • Table 92. Europe New-Born Screening, by Technology USD Million (2019-2024)
  • Table 93. Europe New-Born Screening, by End User USD Million (2019-2024)
  • Table 94. Germany New-Born Screening, by Type USD Million (2019-2024)
  • Table 95. Germany New-Born Screening, by Application USD Million (2019-2024)
  • Table 96. Germany New-Born Screening, by Test USD Million (2019-2024)
  • Table 97. Germany New-Born Screening, by Technology USD Million (2019-2024)
  • Table 98. Germany New-Born Screening, by End User USD Million (2019-2024)
  • Table 99. France New-Born Screening, by Type USD Million (2019-2024)
  • Table 100. France New-Born Screening, by Application USD Million (2019-2024)
  • Table 101. France New-Born Screening, by Test USD Million (2019-2024)
  • Table 102. France New-Born Screening, by Technology USD Million (2019-2024)
  • Table 103. France New-Born Screening, by End User USD Million (2019-2024)
  • Table 104. Italy New-Born Screening, by Type USD Million (2019-2024)
  • Table 105. Italy New-Born Screening, by Application USD Million (2019-2024)
  • Table 106. Italy New-Born Screening, by Test USD Million (2019-2024)
  • Table 107. Italy New-Born Screening, by Technology USD Million (2019-2024)
  • Table 108. Italy New-Born Screening, by End User USD Million (2019-2024)
  • Table 109. United Kingdom New-Born Screening, by Type USD Million (2019-2024)
  • Table 110. United Kingdom New-Born Screening, by Application USD Million (2019-2024)
  • Table 111. United Kingdom New-Born Screening, by Test USD Million (2019-2024)
  • Table 112. United Kingdom New-Born Screening, by Technology USD Million (2019-2024)
  • Table 113. United Kingdom New-Born Screening, by End User USD Million (2019-2024)
  • Table 114. Netherlands New-Born Screening, by Type USD Million (2019-2024)
  • Table 115. Netherlands New-Born Screening, by Application USD Million (2019-2024)
  • Table 116. Netherlands New-Born Screening, by Test USD Million (2019-2024)
  • Table 117. Netherlands New-Born Screening, by Technology USD Million (2019-2024)
  • Table 118. Netherlands New-Born Screening, by End User USD Million (2019-2024)
  • Table 119. Rest of Europe New-Born Screening, by Type USD Million (2019-2024)
  • Table 120. Rest of Europe New-Born Screening, by Application USD Million (2019-2024)
  • Table 121. Rest of Europe New-Born Screening, by Test USD Million (2019-2024)
  • Table 122. Rest of Europe New-Born Screening, by Technology USD Million (2019-2024)
  • Table 123. Rest of Europe New-Born Screening, by End User USD Million (2019-2024)
  • Table 124. MEA New-Born Screening, by Country USD Million (2019-2024)
  • Table 125. MEA New-Born Screening, by Type USD Million (2019-2024)
  • Table 126. MEA New-Born Screening, by Application USD Million (2019-2024)
  • Table 127. MEA New-Born Screening, by Test USD Million (2019-2024)
  • Table 128. MEA New-Born Screening, by Technology USD Million (2019-2024)
  • Table 129. MEA New-Born Screening, by End User USD Million (2019-2024)
  • Table 130. Middle East New-Born Screening, by Type USD Million (2019-2024)
  • Table 131. Middle East New-Born Screening, by Application USD Million (2019-2024)
  • Table 132. Middle East New-Born Screening, by Test USD Million (2019-2024)
  • Table 133. Middle East New-Born Screening, by Technology USD Million (2019-2024)
  • Table 134. Middle East New-Born Screening, by End User USD Million (2019-2024)
  • Table 135. Africa New-Born Screening, by Type USD Million (2019-2024)
  • Table 136. Africa New-Born Screening, by Application USD Million (2019-2024)
  • Table 137. Africa New-Born Screening, by Test USD Million (2019-2024)
  • Table 138. Africa New-Born Screening, by Technology USD Million (2019-2024)
  • Table 139. Africa New-Born Screening, by End User USD Million (2019-2024)
  • Table 140. North America New-Born Screening, by Country USD Million (2019-2024)
  • Table 141. North America New-Born Screening, by Type USD Million (2019-2024)
  • Table 142. North America New-Born Screening, by Application USD Million (2019-2024)
  • Table 143. North America New-Born Screening, by Test USD Million (2019-2024)
  • Table 144. North America New-Born Screening, by Technology USD Million (2019-2024)
  • Table 145. North America New-Born Screening, by End User USD Million (2019-2024)
  • Table 146. United States New-Born Screening, by Type USD Million (2019-2024)
  • Table 147. United States New-Born Screening, by Application USD Million (2019-2024)
  • Table 148. United States New-Born Screening, by Test USD Million (2019-2024)
  • Table 149. United States New-Born Screening, by Technology USD Million (2019-2024)
  • Table 150. United States New-Born Screening, by End User USD Million (2019-2024)
  • Table 151. Canada New-Born Screening, by Type USD Million (2019-2024)
  • Table 152. Canada New-Born Screening, by Application USD Million (2019-2024)
  • Table 153. Canada New-Born Screening, by Test USD Million (2019-2024)
  • Table 154. Canada New-Born Screening, by Technology USD Million (2019-2024)
  • Table 155. Canada New-Born Screening, by End User USD Million (2019-2024)
  • Table 156. Mexico New-Born Screening, by Type USD Million (2019-2024)
  • Table 157. Mexico New-Born Screening, by Application USD Million (2019-2024)
  • Table 158. Mexico New-Born Screening, by Test USD Million (2019-2024)
  • Table 159. Mexico New-Born Screening, by Technology USD Million (2019-2024)
  • Table 160. Mexico New-Born Screening, by End User USD Million (2019-2024)
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. New-Born Screening: by Type(USD Million)
  • Table 172. New-Born Screening Tandem Mass Spectrometry , by Region USD Million (2027-2032)
  • Table 173. New-Born Screening Pulse Oximetry Screening Technology , by Region USD Million (2027-2032)
  • Table 174. New-Born Screening DNA-Based Assays , by Region USD Million (2027-2032)
  • Table 175. New-Born Screening Hearing Screen Technology , by Region USD Million (2027-2032)
  • Table 176. New-Born Screening Others , by Region USD Million (2027-2032)
  • Table 177. New-Born Screening: by Application(USD Million)
  • Table 178. New-Born Screening Hospitals , by Region USD Million (2027-2032)
  • Table 179. New-Born Screening Clinics , by Region USD Million (2027-2032)
  • Table 180. New-Born Screening Nursing Homes , by Region USD Million (2027-2032)
  • Table 181. New-Born Screening Others , by Region USD Million (2027-2032)
  • Table 182. New-Born Screening: by Test(USD Million)
  • Table 183. New-Born Screening Dry blood spot tests , by Region USD Million (2027-2032)
  • Table 184. New-Born Screening Hearing screening tests , by Region USD Million (2027-2032)
  • Table 185. New-Born Screening CCHD screening tests , by Region USD Million (2027-2032)
  • Table 186. New-Born Screening: by Technology(USD Million)
  • Table 187. New-Born Screening Immune assays & enzymatic assays , by Region USD Million (2027-2032)
  • Table 188. New-Born Screening Tandem mass spectrometry , by Region USD Million (2027-2032)
  • Table 189. New-Born Screening Molecular assays , by Region USD Million (2027-2032)
  • Table 190. New-Born Screening Hearing screening technologies , by Region USD Million (2027-2032)
  • Table 191. New-Born Screening Pulse oximetry , by Region USD Million (2027-2032)
  • Table 192. New-Born Screening Other Technologies (Fluorescence, gel electrophoresis and etc.) , by Region USD Million (2027-2032)
  • Table 193. New-Born Screening: by End User(USD Million)
  • Table 194. New-Born Screening Clinical Laboratories , by Region USD Million (2027-2032)
  • Table 195. New-Born Screening Hospitals , by Region USD Million (2027-2032)
  • Table 196. South America New-Born Screening, by Country USD Million (2027-2032)
  • Table 197. South America New-Born Screening, by Type USD Million (2027-2032)
  • Table 198. South America New-Born Screening, by Application USD Million (2027-2032)
  • Table 199. South America New-Born Screening, by Test USD Million (2027-2032)
  • Table 200. South America New-Born Screening, by Technology USD Million (2027-2032)
  • Table 201. South America New-Born Screening, by End User USD Million (2027-2032)
  • Table 202. Brazil New-Born Screening, by Type USD Million (2027-2032)
  • Table 203. Brazil New-Born Screening, by Application USD Million (2027-2032)
  • Table 204. Brazil New-Born Screening, by Test USD Million (2027-2032)
  • Table 205. Brazil New-Born Screening, by Technology USD Million (2027-2032)
  • Table 206. Brazil New-Born Screening, by End User USD Million (2027-2032)
  • Table 207. Argentina New-Born Screening, by Type USD Million (2027-2032)
  • Table 208. Argentina New-Born Screening, by Application USD Million (2027-2032)
  • Table 209. Argentina New-Born Screening, by Test USD Million (2027-2032)
  • Table 210. Argentina New-Born Screening, by Technology USD Million (2027-2032)
  • Table 211. Argentina New-Born Screening, by End User USD Million (2027-2032)
  • Table 212. Rest of South America New-Born Screening, by Type USD Million (2027-2032)
  • Table 213. Rest of South America New-Born Screening, by Application USD Million (2027-2032)
  • Table 214. Rest of South America New-Born Screening, by Test USD Million (2027-2032)
  • Table 215. Rest of South America New-Born Screening, by Technology USD Million (2027-2032)
  • Table 216. Rest of South America New-Born Screening, by End User USD Million (2027-2032)
  • Table 217. Asia Pacific New-Born Screening, by Country USD Million (2027-2032)
  • Table 218. Asia Pacific New-Born Screening, by Type USD Million (2027-2032)
  • Table 219. Asia Pacific New-Born Screening, by Application USD Million (2027-2032)
  • Table 220. Asia Pacific New-Born Screening, by Test USD Million (2027-2032)
  • Table 221. Asia Pacific New-Born Screening, by Technology USD Million (2027-2032)
  • Table 222. Asia Pacific New-Born Screening, by End User USD Million (2027-2032)
  • Table 223. China New-Born Screening, by Type USD Million (2027-2032)
  • Table 224. China New-Born Screening, by Application USD Million (2027-2032)
  • Table 225. China New-Born Screening, by Test USD Million (2027-2032)
  • Table 226. China New-Born Screening, by Technology USD Million (2027-2032)
  • Table 227. China New-Born Screening, by End User USD Million (2027-2032)
  • Table 228. Japan New-Born Screening, by Type USD Million (2027-2032)
  • Table 229. Japan New-Born Screening, by Application USD Million (2027-2032)
  • Table 230. Japan New-Born Screening, by Test USD Million (2027-2032)
  • Table 231. Japan New-Born Screening, by Technology USD Million (2027-2032)
  • Table 232. Japan New-Born Screening, by End User USD Million (2027-2032)
  • Table 233. India New-Born Screening, by Type USD Million (2027-2032)
  • Table 234. India New-Born Screening, by Application USD Million (2027-2032)
  • Table 235. India New-Born Screening, by Test USD Million (2027-2032)
  • Table 236. India New-Born Screening, by Technology USD Million (2027-2032)
  • Table 237. India New-Born Screening, by End User USD Million (2027-2032)
  • Table 238. South Korea New-Born Screening, by Type USD Million (2027-2032)
  • Table 239. South Korea New-Born Screening, by Application USD Million (2027-2032)
  • Table 240. South Korea New-Born Screening, by Test USD Million (2027-2032)
  • Table 241. South Korea New-Born Screening, by Technology USD Million (2027-2032)
  • Table 242. South Korea New-Born Screening, by End User USD Million (2027-2032)
  • Table 243. Taiwan New-Born Screening, by Type USD Million (2027-2032)
  • Table 244. Taiwan New-Born Screening, by Application USD Million (2027-2032)
  • Table 245. Taiwan New-Born Screening, by Test USD Million (2027-2032)
  • Table 246. Taiwan New-Born Screening, by Technology USD Million (2027-2032)
  • Table 247. Taiwan New-Born Screening, by End User USD Million (2027-2032)
  • Table 248. Australia New-Born Screening, by Type USD Million (2027-2032)
  • Table 249. Australia New-Born Screening, by Application USD Million (2027-2032)
  • Table 250. Australia New-Born Screening, by Test USD Million (2027-2032)
  • Table 251. Australia New-Born Screening, by Technology USD Million (2027-2032)
  • Table 252. Australia New-Born Screening, by End User USD Million (2027-2032)
  • Table 253. Rest of Asia-Pacific New-Born Screening, by Type USD Million (2027-2032)
  • Table 254. Rest of Asia-Pacific New-Born Screening, by Application USD Million (2027-2032)
  • Table 255. Rest of Asia-Pacific New-Born Screening, by Test USD Million (2027-2032)
  • Table 256. Rest of Asia-Pacific New-Born Screening, by Technology USD Million (2027-2032)
  • Table 257. Rest of Asia-Pacific New-Born Screening, by End User USD Million (2027-2032)
  • Table 258. Europe New-Born Screening, by Country USD Million (2027-2032)
  • Table 259. Europe New-Born Screening, by Type USD Million (2027-2032)
  • Table 260. Europe New-Born Screening, by Application USD Million (2027-2032)
  • Table 261. Europe New-Born Screening, by Test USD Million (2027-2032)
  • Table 262. Europe New-Born Screening, by Technology USD Million (2027-2032)
  • Table 263. Europe New-Born Screening, by End User USD Million (2027-2032)
  • Table 264. Germany New-Born Screening, by Type USD Million (2027-2032)
  • Table 265. Germany New-Born Screening, by Application USD Million (2027-2032)
  • Table 266. Germany New-Born Screening, by Test USD Million (2027-2032)
  • Table 267. Germany New-Born Screening, by Technology USD Million (2027-2032)
  • Table 268. Germany New-Born Screening, by End User USD Million (2027-2032)
  • Table 269. France New-Born Screening, by Type USD Million (2027-2032)
  • Table 270. France New-Born Screening, by Application USD Million (2027-2032)
  • Table 271. France New-Born Screening, by Test USD Million (2027-2032)
  • Table 272. France New-Born Screening, by Technology USD Million (2027-2032)
  • Table 273. France New-Born Screening, by End User USD Million (2027-2032)
  • Table 274. Italy New-Born Screening, by Type USD Million (2027-2032)
  • Table 275. Italy New-Born Screening, by Application USD Million (2027-2032)
  • Table 276. Italy New-Born Screening, by Test USD Million (2027-2032)
  • Table 277. Italy New-Born Screening, by Technology USD Million (2027-2032)
  • Table 278. Italy New-Born Screening, by End User USD Million (2027-2032)
  • Table 279. United Kingdom New-Born Screening, by Type USD Million (2027-2032)
  • Table 280. United Kingdom New-Born Screening, by Application USD Million (2027-2032)
  • Table 281. United Kingdom New-Born Screening, by Test USD Million (2027-2032)
  • Table 282. United Kingdom New-Born Screening, by Technology USD Million (2027-2032)
  • Table 283. United Kingdom New-Born Screening, by End User USD Million (2027-2032)
  • Table 284. Netherlands New-Born Screening, by Type USD Million (2027-2032)
  • Table 285. Netherlands New-Born Screening, by Application USD Million (2027-2032)
  • Table 286. Netherlands New-Born Screening, by Test USD Million (2027-2032)
  • Table 287. Netherlands New-Born Screening, by Technology USD Million (2027-2032)
  • Table 288. Netherlands New-Born Screening, by End User USD Million (2027-2032)
  • Table 289. Rest of Europe New-Born Screening, by Type USD Million (2027-2032)
  • Table 290. Rest of Europe New-Born Screening, by Application USD Million (2027-2032)
  • Table 291. Rest of Europe New-Born Screening, by Test USD Million (2027-2032)
  • Table 292. Rest of Europe New-Born Screening, by Technology USD Million (2027-2032)
  • Table 293. Rest of Europe New-Born Screening, by End User USD Million (2027-2032)
  • Table 294. MEA New-Born Screening, by Country USD Million (2027-2032)
  • Table 295. MEA New-Born Screening, by Type USD Million (2027-2032)
  • Table 296. MEA New-Born Screening, by Application USD Million (2027-2032)
  • Table 297. MEA New-Born Screening, by Test USD Million (2027-2032)
  • Table 298. MEA New-Born Screening, by Technology USD Million (2027-2032)
  • Table 299. MEA New-Born Screening, by End User USD Million (2027-2032)
  • Table 300. Middle East New-Born Screening, by Type USD Million (2027-2032)
  • Table 301. Middle East New-Born Screening, by Application USD Million (2027-2032)
  • Table 302. Middle East New-Born Screening, by Test USD Million (2027-2032)
  • Table 303. Middle East New-Born Screening, by Technology USD Million (2027-2032)
  • Table 304. Middle East New-Born Screening, by End User USD Million (2027-2032)
  • Table 305. Africa New-Born Screening, by Type USD Million (2027-2032)
  • Table 306. Africa New-Born Screening, by Application USD Million (2027-2032)
  • Table 307. Africa New-Born Screening, by Test USD Million (2027-2032)
  • Table 308. Africa New-Born Screening, by Technology USD Million (2027-2032)
  • Table 309. Africa New-Born Screening, by End User USD Million (2027-2032)
  • Table 310. North America New-Born Screening, by Country USD Million (2027-2032)
  • Table 311. North America New-Born Screening, by Type USD Million (2027-2032)
  • Table 312. North America New-Born Screening, by Application USD Million (2027-2032)
  • Table 313. North America New-Born Screening, by Test USD Million (2027-2032)
  • Table 314. North America New-Born Screening, by Technology USD Million (2027-2032)
  • Table 315. North America New-Born Screening, by End User USD Million (2027-2032)
  • Table 316. United States New-Born Screening, by Type USD Million (2027-2032)
  • Table 317. United States New-Born Screening, by Application USD Million (2027-2032)
  • Table 318. United States New-Born Screening, by Test USD Million (2027-2032)
  • Table 319. United States New-Born Screening, by Technology USD Million (2027-2032)
  • Table 320. United States New-Born Screening, by End User USD Million (2027-2032)
  • Table 321. Canada New-Born Screening, by Type USD Million (2027-2032)
  • Table 322. Canada New-Born Screening, by Application USD Million (2027-2032)
  • Table 323. Canada New-Born Screening, by Test USD Million (2027-2032)
  • Table 324. Canada New-Born Screening, by Technology USD Million (2027-2032)
  • Table 325. Canada New-Born Screening, by End User USD Million (2027-2032)
  • Table 326. Mexico New-Born Screening, by Type USD Million (2027-2032)
  • Table 327. Mexico New-Born Screening, by Application USD Million (2027-2032)
  • Table 328. Mexico New-Born Screening, by Test USD Million (2027-2032)
  • Table 329. Mexico New-Born Screening, by Technology USD Million (2027-2032)
  • Table 330. Mexico New-Born Screening, by End User USD Million (2027-2032)
  • Table 331. Research Programs/Design for This Report
  • Table 332. Key Data Information from Secondary Sources
  • Table 333. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global New-Born Screening: by Type USD Million (2019-2024)
  • Figure 5. Global New-Born Screening: by Application USD Million (2019-2024)
  • Figure 6. Global New-Born Screening: by Test USD Million (2019-2024)
  • Figure 7. Global New-Born Screening: by Technology USD Million (2019-2024)
  • Figure 8. Global New-Born Screening: by End User USD Million (2019-2024)
  • Figure 9. South America New-Born Screening Share (%), by Country
  • Figure 10. Asia Pacific New-Born Screening Share (%), by Country
  • Figure 11. Europe New-Born Screening Share (%), by Country
  • Figure 12. MEA New-Born Screening Share (%), by Country
  • Figure 13. North America New-Born Screening Share (%), by Country
  • Figure 14. Global New-Born Screening share by Players 2024 (%)
  • Figure 15. Global New-Born Screening share by Players (Top 3) 2024(%)
  • Figure 16. Global New-Born Screening share by Players (Top 5) 2024(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GE Healthcare (Chicago, United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare (Chicago, United States) Revenue: by Geography 2024
  • Figure 20. Trivitron Healthcare (Chennai, India) Revenue, Net Income and Gross profit
  • Figure 21. Trivitron Healthcare (Chennai, India) Revenue: by Geography 2024
  • Figure 22. AB Sciex (Framingham, United States) Revenue, Net Income and Gross profit
  • Figure 23. AB Sciex (Framingham, United States) Revenue: by Geography 2024
  • Figure 24. PerkinElmer (Waltham, United States) Revenue, Net Income and Gross profit
  • Figure 25. PerkinElmer (Waltham, United States) Revenue: by Geography 2024
  • Figure 26. Bio-Rad Laboratories (Hercules, United States) Revenue, Net Income and Gross profit
  • Figure 27. Bio-Rad Laboratories (Hercules, United States) Revenue: by Geography 2024
  • Figure 28. Agilent Technologies (Santa Clara, United States) Revenue, Net Income and Gross profit
  • Figure 29. Agilent Technologies (Santa Clara, United States) Revenue: by Geography 2024
  • Figure 30. Covidien (Mansfield, United States) (Note: Acquired by Medtronic) Revenue, Net Income and Gross profit
  • Figure 31. Covidien (Mansfield, United States) (Note: Acquired by Medtronic) Revenue: by Geography 2024
  • Figure 32. Masimo (Irvine, United States) Revenue, Net Income and Gross profit
  • Figure 33. Masimo (Irvine, United States) Revenue: by Geography 2024
  • Figure 34. Waters Corporation (Milford, United States) Revenue, Net Income and Gross profit
  • Figure 35. Waters Corporation (Milford, United States) Revenue: by Geography 2024
  • Figure 36. Natus Medical (Pleasanton, United States) Revenue, Net Income and Gross profit
  • Figure 37. Natus Medical (Pleasanton, United States) Revenue: by Geography 2024
  • Figure 38. Global New-Born Screening: by Type USD Million (2027-2032)
  • Figure 39. Global New-Born Screening: by Application USD Million (2027-2032)
  • Figure 40. Global New-Born Screening: by Test USD Million (2027-2032)
  • Figure 41. Global New-Born Screening: by Technology USD Million (2027-2032)
  • Figure 42. Global New-Born Screening: by End User USD Million (2027-2032)
  • Figure 43. South America New-Born Screening Share (%), by Country
  • Figure 44. Asia Pacific New-Born Screening Share (%), by Country
  • Figure 45. Europe New-Born Screening Share (%), by Country
  • Figure 46. MEA New-Born Screening Share (%), by Country
  • Figure 47. North America New-Born Screening Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GE Healthcare (Chicago, United States)
  • Trivitron Healthcare (Chennai, India)
  • AB Sciex (Framingham, United States)
  • PerkinElmer (Waltham, United States)
  • Bio-Rad Laboratories (Hercules, United States)
  • Agilent Technologies (Santa Clara, United States)
  • Covidien (Mansfield, United States) (Note: Acquired by Medtronic)
  • Masimo (Irvine, United States)
  • Waters Corporation (Milford, United States)
  • Natus Medical (Pleasanton, United States)
Select User Access Type

Key Highlights of Report


Feb 2025 234 Pages 63 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global New-Born Screening Quantitative research analysis
Global New-Born Screening Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GE Healthcare (Chicago, United States), Trivitron Healthcare (Chennai, India), AB Sciex (Framingham, United States), PerkinElmer (Waltham, United States), Bio-Rad Laboratories (Hercules, United States), Agilent Technologies (Santa Clara, United States), Covidien (Mansfield, United States) (Note: Acquired by Medtronic), Masimo (Irvine, United States), Waters Corporation (Milford, United States) and Natus Medical (Pleasanton, United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for New-Born Screening Market during projected period 2024-2032.
The New-Born Screening market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global New-Born Screening Report?

Have a Query? Click Here

Other Related Reports

Phenolic Antioxidant Comprehensive Study by Type (Natural, Synthetic), Application (Automotive, Construction, Electronics, Packaging, Defense, Others), Packaging (Bottle, Bag, Others), Sales Channel ...
$ 3450
Contact Lenses Comprehensive Study by Type (Rigid Contact Lenses, Soft Contact Lenses, Hybrid Contact Lenses), Application (Corrective Lenses, Therapeutic Lenses, Cosmetic Lenses and Lifestyle-Orient...
$ 3650
Machine Condition Monitoring Comprehensive Study by Deployment Mode (On-Premise, Cloud Based), Technology (Acoustic Emission Monitoring, Ultrasound Monitoring, Infrared Thermography, Vibration Monito...
$ 3800
Veterinary Equipment And Disposables Comprehensive Study by Type (Consumables, Anesthesia Machines, Ventilators, Patient Monitoring, Oxygen Masks, Infusion Pumps), Animal Type (Companion, Livestock),...
$ 3450
Hydrazine Hydrate Comprehensive Study by Type (35 % Concentration, 40 % Concentration, 55 % Concentration, 80 % Concentration, Others), Application (Pharmaceuticals, Polymerization & Blowing Agents, ...
$ 3750
Acoustic Saxophone Comprehensive Study by Type (Sopranissimo, Soprano, Sopranino, Bass, Contrabass, Subcontrabass, Alto, Tenor, Baritone), Application (Classical Music, • Concert Bands, • Chamber Mus...
$ 3800